Genlab INC
Genlab INC was paid $80K by Medicaid between Mar 2021 and Mar 2024, across 31 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 56% of everything it billed.
LAS VEGAS, NV 89106
Next to other Clinical Medical Laboratory providers in Nevada
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 8,079 | $3K | |
| 2022 | 7,790 | $45K | |
| 2023 | 809 | $33K | |
| 2024incomplete | 110 | $0.00 |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 56% | 800 | 743 | $45K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 759 | 704 | $15K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 12% | 742 | 611 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.6% | 858 | 698 | $2K |
| 80061 | Lipid panel | 1.9% | 1,208 | 1,009 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 166 | 149 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 1,217 | 994 | $1K |
| 80050 | General health panel | 1.3% | 44 | 42 | $1K |
| 82607 | <1% | 363 | 307 | $668.20 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,444 | 1,194 | $509.76 |
| 80053 | Comprehensive metabolic panel | <1% | 1,365 | 1,153 | $483.07 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,071 | 902 | $378.51 |
19 more codes
| 81000 | <1% | 749 | $181.44 | |
| 82652 | <1% | 20 | $105.08 | |
| 84153 | <1% | 67 | $87.85 | |
| 84550 | <1% | 245 | $64.68 | |
| 84439 | <1% | 234 | $55.35 | |
| 83540 | <1% | 39 | $35.01 | |
| 81001 | <1% | 83 | $34.56 | |
| 84436 | <1% | 127 | $23.45 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 207 | $16.53 |
| 85610 | <1% | 694 | $16.14 | |
| 84481 | <1% | 154 | $11.56 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 551 | $0.00 |
| 86480 | 0% | 55 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 1,104 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 1,986 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 374 | $0.00 |
| 84480 | 0% | 18 | $0.00 | |
| 85027 | 0% | 15 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.